Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodoacetamide SCHEMBL21543894 | 0.93 | POLB (0.63) | POLBTDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL21765862 | 0.89 | MEN1 (0.54) | POLBALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2093668 | 0.85 | POLB (0.76) | POLBTDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL8141144 | 0.85 | POLB (1.00) | POLBTDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL16438781 | 0.84 | POLB (0.68) | POLBTDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL14578751 | 0.83 | POLB (0.85) | POLBTDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL6003020 | 0.82 | POLB (0.70) | POLBTDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL10852762 | 0.81 | POLB (0.47) | POLBHDAC1HDAC8HDAC6HDAC7 | |
| SCHEMBL2093671 | 0.81 | POLB (0.76) | POLBTDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL10865344 | 0.81 | CYP1A1 (0.60) | POLBHDAC4ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | claimed |
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-06 | — | — | US | claimed |
| US-20210072254-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | DANA-FARBER CANCER INSTITUTE, INC. | 2021-03-11 | — | — | US | claimed |
| EP-3545314-A1 | REAGENTS AND METHODS FOR ANALYSIS OF PROTEINS AND METABOLITES TARGETED BY COVALENT PROBES | Dana-Farber Cancer Institute, Inc. (US) | 2019-10-02 | — | — | EP | claimed |
| WO-2018098473-A1 | REAGENTS AND METHODS FOR ANALYSIS OF PROTEINS AND METABOLITES TARGETED BY COVALENT PROBES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | claimed |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210072254-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | DANA-FARBER CANCER INSTITUTE, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210072254-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | DANA-FARBER CANCER INSTITUTE, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20140309409-A1 | Sialic Acid Derivatives | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2014-10-16 | — | — | US | disclosed |
| US-8765936-B2 | Sialic acid derivatives | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2014-07-01 | — | — | US | disclosed |
| US-20130096294-A1 | SIALIC ACID DERIVATIVES | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2013-04-18 | — | — | US | disclosed |
| US-20080293660-A1 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2008-11-27 | — | — | US | disclosed |
| US-7351855-B2 | Chemically defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070254851-A1 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| US-7208156-B2 | Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| US-7163683-B2 | Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293660-A1 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | SSB, PCNA, NCL | POLB 78/4885TDP1 398/4885HDAC3 1080/4885 |
| US-20140309409-A1 | Sialic Acid Derivatives | NEU2, NEU4, NEU1 | POLB 4602/4885TDP1 4159/4885HDAC3 279/4885 |
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | POLB 3536/4885TDP1 3437/4885HDAC3 1109/4885 |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | POLB 3536/4885TDP1 3437/4885HDAC3 1109/4885 |
| US-20210072254-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | PTMS, SRMS, HSP90B1 | POLB 3536/4885TDP1 3437/4885HDAC3 1109/4885 |
| US-20070254851-A1 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | SSB, PCNA, NCL | POLB 78/4885TDP1 398/4885HDAC3 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.